Cannabinoid receptor type 2 ligands: an analysis of granted patents since 2010.

The G-protein-coupled cannabinoid receptor type 2 (CBR) is a key element of the endocannabinoid (EC) system. EC/CBR signaling has significant therapeutic potential in major pathologies affecting humans such as allergies, neurodegenerative disorders, inflammation or ocular diseases. CBR agonism exerts anti-inflammatory and tissue protective effects in preclinical animal models of cardiovascular, gastrointestinal, liver, kidney, lung and neurodegenerative disorders.